Autism, gut-blood-brain barrier, and mast cells

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 479-483

  Theoharides, Theoharis C ^a   Doyle, Robert ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYPROHEPTADINE; CYTOKINE; FREE RADICAL; HALOPERIDOL; IMMUNOGLOBULIN G4; INTERLEUKIN 6; PLACEBO; PROSTAGLANDIN; SEROTONIN;

ABDOMINAL PAIN; AUTISM; BLOOD BRAIN BARRIER; CELL ACTIVATION; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; FOOD ALLERGY; GASTROINTESTINAL DISEASE; GUT BLOOD BRAIN BARRIER; HUMAN; IMMUNE SYSTEM; MACROPHAGE MIGRATION; MAST CELL; MIGRAINE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; NUTRITIONAL INTOLERANCE; ONSET AGE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOALLERGOSORBENT TEST; SKIN TINGLING; STRESS; THROMBOCYTE; ANIMAL; CHILD; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; AUTISTIC DISORDER; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CHILD; GASTROINTESTINAL DISEASES; HUMANS; MAST CELLS;

EID: 58149123111     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181845f48     Document Type: Editorial

References (95)

1. Fiith U. Autism. Soi Am. 1993;268:108-114.
2. Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006;118:e139-e150.
3. Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics. 2007;120:1183-1215.
4. Stehr-Green P, Tull P, Stellfeld M, et al. Autism and thimerosal- containing vaccines: lack of consistent evidence for an association. Am JPrevMed. 2003;25:101-106.
5. D'Souza Y, Fombonne E, Ward BJ. No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. Pediatrics. 2006;118:1664-1675.
6. DeStefano F. Vaccines and autism: evidence does not support a causal association. Clin Pharmacol Ther. 2007;82:756-759.
7. Baker JP. Mercury, vaccines, and autism: one controversy, three histories. Am JPublic Health. 2008;98:244-253.
8. Fombonne E. Thimerosal disappears but autism remains. Arch Gen Psychiatry. 2008;65:15-16.
9. White JF. Intestinal pathophysiology in autism. Exp Biol Med (May-wood). 2003;228:639-649.
10. Levy SE, Souders MC, Ittenbach RF, et al. Relationship of dietary intake to gastrointestinal symptoms in children with autistic spectrum disorders. Biol Psychiatry. 2007;61:492-197.
11. Elder JH, Shankar M, Shuster J, et al. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord. 2006;36:413-420.
12. Alpert M. The autism diet. Sci Am. 2007;296:19-20.
13. Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ. 2002;325:419-421.
14. Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr. 2005;94:386-393.
15. Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med. 2006;160:825-830.
16. Venter C, Pereira B, Voigt K, et al. Prevalence and cumulative incidence of food hypersensitivity in the first 3 years of life. Allergy. 2008;63:354-359.
17. Teufel M, Biedermann T, Rapps N, et al. Psychological burden of food allergy. World J Gastroenterol. 2007;13:3456-3465.
18. Vatn MH. Food intolerance and psychosomatic experience. Scand J Work Environ Health. 1997;23(suppl 3):75-78.
19. Ortolani C, Pastorello EA. Food allergies and food intolerances. Best Pract Res Clin Gastroenterol. 2006;20:467-483.
20. Kruszewski J, Raczka A, Klos M, et al. High serum levels of allergen specific IgG-4 (asIgG-4) for common food allergens in healthy blood donors. Arch Immunol Ther Exp (Warsz). 1994;42:259-261.
21. Morrow JD, Margolies GR, Rowland J, et al. Evidence that histamine is the causative toxin of scombroid-fish poisoning. NEnglJ Med. 1991;324:716-720.
22. McLauchlin J, Little CL, Grant KA, et al. Scombrotoxic fish poisoning. J Public Health (Oxf). 2006;28:61-62.
23. Lundberg PO. Abdominal migraine-diagnosis and therapy. Headache. 1975;15:122-125.
24. Olness K, Hall H, Rozniecki JJ, et al. Mast cell activation in children with migraine before and after training in self-regulation. Headache. 1999;39:101-107.
25. Gillott A, Standen PJ. Levels of anxiety and sources of stress in adults with autism. J Intellect Disabil. 2007;11:359-370.
26. Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy. Implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther. 2007;116:207-235.
27. Farhadi A, Fields JZ, Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J Gastroenterol. 2007;13:3027-3030.
28. Theoharides TC, Donelan J, Kandere-Grzybowska K, et al. The role of mast cells in migraine pathophysiology. Brain Res Rev. 2005;49:65-76.
29. Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci. 2007;12:1615-1628.
30. Vojdani A, Campbell AW, Anyanwu E, et al. Antibodies to neuron- specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol. 2002;129:168-177.
31. Jansen LM, Gispen-de Wied CC, van der Gaag RJ, et al. Differentiation between autism and multiple complex developmental disorder in response to psychosocial stress. Neuropsychopharmacology. 2003;28: 582-590.
32. Tani P, Lindberg N, Matto V, et al. Higher plasma ACTH levels in adults with Asperger syndrome. JPsychosom Res. 2005;58:533-536.
33. Theoharides TC, Letourneau R, Patra P, et al. Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. Dig Dis Sci. 1999;44:87S-93S.
34. Belova I, Jonsson G. Blood-brain barrier permeability and immobilization stress. Acta Physiol Scand. 1982;116:21-29.
35. Esposito P, Gheorghe D, Kandere K, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res. 2001;888:117-127.
36. Theoharides TC. Mast cells: the immune gate to the brain. Life Sci. 1990;46:607-617.
37. Silver R, Silverman A-J, Vitkovic L, et al. Mast cells in the brain: evidence and functional significance. Trends Neurosci. 1996;19:25-31.
38. Esposito P, Chandler N, Kandere-Grzybowska K, et al. Corticotropin- releasing hormone (CRH) and brain mast cells regulate blood-brain- barrier permeability induced by acute stress. J Pharmacol Exp Ther. 2002;303:1061-1066.
39. Theoharides TC, Spanos CP, Pang X, et al. Stress-induced intracranial mast cell degranulation. A corticotropin releasing hormone-mediated effect. Endocrinology. 1995;136:5745-5750.
40. Kubler A, Rothacher G, Knappertz VA, et al. Intra- and extracerebral blood flow changes and flushing after intravenous injection of human corticotrophin-releasing hormone. Clin Invest. 1994;72:331-336.
41. Theoharides TC, Singh LK, Boucher W, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. Endocrinology. 1998;139:403-U3.
42. Crompton R, Clifton VL, Bisits AT, et al. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. J Clin Endocrinol Metab. 2003;88:5427-5432.
43. Spanos C, Pang X, Ligris K, et al. Stress-induced bladder mast cell activation: implications for interstitial cystitis. JUrol. 1997;157:669-672.
44. Castagliuolo I, LaMont JT, Qiu B, et al. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am J Physiol. 1996;271:884-892.
45. Wallon C, Yang P, Keita AV, et al. Corticotropin releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut. 2008;57:50-58.
46. Theoharides TC, Kalogeromitros D. The critical role of mast cell in allergy and inflammation. Ann NY Acad Sci. 2006;1088:78-99.
47. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749-786.
48. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004; 146:1-12.
49. Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, et al. Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. Brain Res. 1999;849:1-15.
50. Stead RH, Dixon MF, Bramwell NH, et al. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology. 1989;97:575-585.
51. Purcell WM, Atterwill CK. Mast cells in neuroimmune function: neurotoxicological and neuropharmacological perspectives. Neurochem Res. 1995;20:521-532.
52. Blank U, Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol. 2004;25:266-273.
53. Janiszewski J, Bienenstock J, Blennerhassett MG. Picomolar doses of substance P trigger electrical responses in mast cells without degranulation. Am J Physiol. 1994;267:C138-C145.
54. Redegeld FA, Nijkamp FP. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? Trends Immunol. 2005;24:181-185.
55. Carraway R, Cochrane DE, Lansman JB, et al. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. J Physiol. 1982;323:403-414.
56. Kim KS, Wass CA, Cross AS, et al. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res. 1992;11:293-298.
57. Jyonouchi H, Geng L, Ruby A, et al. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology. 2005;51:77-85.
58. Chez MG, Dowling T, Patel PB, et al. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol. 2007;36:361-365.
59. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445-452.
60. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation. 2008;5:2.
61. Yao Y, Walsh WJ, McGinnis WR, et al. Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol. 2006;63: 1161-1164.
62. Theoharides TC, Kempuraj D, Tagen M, et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev. 2007;217:65-78.
63. Theoharides TC, Bondy PK, Tsakalos ND, et al. Differential release of serotonin and histamine from mast cells. Nature. 1982;297: 229-231.
64. Kandere-Grzybowska K, Letourneau R, Kempuraj D, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol. 2003;171:4830-4836.
65. Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol. 2005;174:7665-7675.
66. Boesiger J, Tsai M, Maurer M, et al. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of FOε receptor I expression. J Exp Med. 1998;188:1135-1145.
67. 206. Mol Biol Cell. 1998;9: 875-884.
68. Theoharides TC, Weinkauf C, Conti P. Brain cytokines and neuro- psychiatric disorders. J Clin Psychopharmacol. 2004;24:577-581.
69. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993;77:1690-1694.
70. Ashwood P, Wills S, Van de WJ. The immune response in autism: a new frontier for autism research. J Leukoc Biol. 2006;80:1-15.
71. Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry. 2005;17:485-495.
72. Cohly HH, Panja A. Immunological findings in autism. Int Rev Neurobiol. 2005;71:317-341.
73. Ashwood P, Anthony A, Torrente F, et al. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J Clin Immunol. 2004;24:664-673.
74. Conti P, Kempuraj D, Kandere K, et al. IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett. 2003;86:123-129.
75. DeFelice ML, Ruchelli ED, Markowitz JE, et al. Intestinal cytokines in children with pervasive developmental disorders. Am J Gastroenterol. 2003;98:1777-1782.
76. Weizman A, Weizman R, Szekely GA, et al. Abnormal immune response to brain tissue antigen in the syndrome of autism. Am J Psychiatry. 1982;139:1462-1465.
77. Conti P, Pang X, Boucher W, et al. Impact of Rantes and MCP-1 chemokines on in vivo basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood. 1997;89:4120-4127.
78. Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother. 2007;8:1579-1603.
79. Broadstock M, Doughty C, Eggleston M. Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder. Autism. 2007;11:335-348.
80. Akhondzadeh S, Erfani S, Mohammadi MR, et al. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. J Clin Pharm Ther. 2004;29:145-150.
81. Hranilovic D, Bujas-Petkovic Z, Vragovic R, et al. Hyperseroto- nemia in adults with autistic disorder. J Autism Dev Disord. 2007;37: 1934-1940.
82. Theoharides TC, Kops SK, Bondy PK, et al. Differential release of serotonin without comparable histamine under diverse conditions in the rat mast cell. Biochem Pharmacol. 1985;34:1389-1398.
83. Worawattanakul M, Rhoads JM, Lichtman SN, et al. Abdominal migraine: prophylactic treatment and follow-up. J Pediatr Gastroenterol Nutr. 1999;28:37-40.
84. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am JMed Genet B Neuropsychiatr Genet. 2006;141:947-956.
85. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80:1611-1617.
86. Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25:563-568.
87. Gravanis A, Margioris AN. The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr Med Chem. 2005;12:1503-1512.
88. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev. 2000;52:673-751.
89. Kempuraj D, Madhappan B, Christodoulou S, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol. 2005;145:934-944.
90. Theoharides TC, Bielory L. Mast cells and mast cell mediators as targets ofdietary supplements. Ann AllergyAsthma Immunol. 2004;93:S24-S34.
91. Beretz A, Cazenave JP, Anton R. Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: structure-activity relationships. Agents Actions. 1982;12:382-387.
92. Grigorenko EL, Han SS, Yrigollen CM, et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics. 2008;22: e438-e445.
93. Pan W, Kastin AJ. Prog Neurobiol. 2008;84:148-156.
94. Deth R, Muratore C, Benzecry J, et al. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology. 2008;29:190-201.
95. Theoharides TC, Doyle R, Francis K, et al. Novel therapeutic targets for autism. Trends Pharmacol Sci. 2008;29:375-382.